methacetin has been researched along with Chronic Liver Failure in 4 studies
methacetin: RN given refers to parent cpd
methacetin : A member of the class of acetamides that is paracetamol in which the hydrogen of phenolic hydroxy group has been replaced by a methyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this pilot study, methacetin breath testing predicted the risk of liver-related death and development/exacerbation of ascites more accurately than MELD ⩾15 or ⩾19." | 3.81 | Use of the methacetin breath test to classify the risk of cirrhotic complications and mortality in patients evaluated/listed for liver transplantation. ( Brown, K; Gordon, SC; Ilan, Y; Lalazar, G; Mizrahi, M; Reuben, A; Sanyal, A; Stravitz, RT, 2015) |
| "Liver function of 167 chronic liver failure patients without hepatocellular carcinoma was prospectively investigated when they were evaluated for liver transplantation." | 1.42 | Prognostic value of enzymatic liver function for the estimation of short-term survival of liver transplant candidates: a prospective study with the LiMAx test. ( Jara, M; Lüttgert, K; Malinowski, M; Neuhaus, P; Schott, E; Stockmann, M, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gairing, SJ | 1 |
| Kuchen, R | 1 |
| Müller, L | 1 |
| Cankaya, A | 1 |
| Weerts, J | 1 |
| Kapucu, A | 1 |
| Sachse, S | 1 |
| Zimpel, C | 1 |
| Stoehr, F | 1 |
| Pitton, MB | 1 |
| Mittler, J | 1 |
| Straub, BK | 1 |
| Marquardt, JU | 1 |
| Schattenberg, JM | 1 |
| Labenz, C | 1 |
| Kloeckner, R | 1 |
| Weinmann, A | 1 |
| Galle, PR | 1 |
| Wörns, MA | 1 |
| Foerster, F | 1 |
| Jara, M | 2 |
| Dziodzio, T | 1 |
| Malinowski, M | 2 |
| Lüttgert, K | 2 |
| Nikolov, R | 1 |
| Ritschl, PV | 1 |
| Öllinger, R | 1 |
| Pratschke, J | 1 |
| Stockmann, M | 2 |
| Schott, E | 1 |
| Neuhaus, P | 1 |
| Stravitz, RT | 1 |
| Reuben, A | 1 |
| Mizrahi, M | 1 |
| Lalazar, G | 1 |
| Brown, K | 1 |
| Gordon, SC | 1 |
| Ilan, Y | 1 |
| Sanyal, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| 13C-Methacetin Breath Test for the Prediction of Outcome in in Acute Liver Injury or Acute Liver Failure[NCT02786836] | Phase 2/Phase 3 | 76 participants (Actual) | Interventional | 2016-06-10 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The relationship between the cPDR (cumulative PDR of metabolized 13C-Methacetin 20 minutes after ingestion) in single time points of MBT measurements and TFS and non-TFS (death/transplant) at Day 21. (NCT02786836)
Timeframe: The first MBT reading either on Day 1 or Day 2 and Day 21
| Intervention | percentage per hour (Mean) | |
|---|---|---|
| Day 1 or 2 MBT/transplant free survival at Day 21 | Day 1 or 2 MBT & Day 21 non-TFS | |
| 13C-Methacetin Breath Test (MBT) | 1.4 | 0.2 |
Peak PDR is the maximal percent dose recovery (PDR) rate which reflects the maximum rate of metabolism of 13C-methacetin measured as the change in 13CO2 / 12CO2 (normal carbon dioxide) ratio after ingestion of 13C-methacetin normalized using the patient's height and weight. The distributions of mean PDR Peak values were compared between TFS (transplant free survival) and non-TFS (death/transplant) at Day 21. (NCT02786836)
Timeframe: Days 1 and 21
| Intervention | percentage per hour (Mean) | |
|---|---|---|
| Mean Peak PDR for TFS subjects at Day 21 | Mean Peak PDR for non-TFS subjects at Day 21 | |
| 13C-Methacetin Breath Test (MBT) | 10.2 | 1.9 |
This outcome is similar to the peak PDR defined in the primary outcome but as a secondary we are looking at Day 1 or Day 2 peak PDR values. Peak PDR is the maximal percent dose recovery (PDR) rate which reflects the maximum rate of metabolism of 13C-methacetin measured as the change in 13CO2 / 12CO2 ratio after ingestion of 13C-methacetin normalized using the patient's height and weight. The distributions of mean PDR Peak values were compared between TFS and non-TFS (death/transplant) at Day 21. (NCT02786836)
Timeframe: The first MBT reading either on Day 1 or Day 2 and Day 21
| Intervention | percentage per hour (Mean) | |
|---|---|---|
| Day 1 or 2 MBT & Day 21 TFS | Day 1 or 2 MBT & Day 21 non-TFS | |
| 13C-Methacetin Breath Test (MBT) | 9.1 | 2.3 |
4 other studies available for methacetin and Chronic Liver Failure
| Article | Year |
|---|---|
13 C-Methacetin Breath Test Predicts Survival in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.
Topics: Albumins; Bilirubin; Breath Tests; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; End St | 2022 |
Prospective Assessment of Liver Function by an Enzymatic Liver Function Test to Estimate Short-Term Survival in Patients with Liver Cirrhosis.
Topics: Acetamides; Breath Tests; Carbon Dioxide; Carbon Isotopes; Cohort Studies; Creatinine; Cytochrome P- | 2019 |
Prognostic value of enzymatic liver function for the estimation of short-term survival of liver transplant candidates: a prospective study with the LiMAx test.
Topics: Acetamides; End Stage Liver Disease; Female; Follow-Up Studies; Humans; Indocyanine Green; Internati | 2015 |
Use of the methacetin breath test to classify the risk of cirrhotic complications and mortality in patients evaluated/listed for liver transplantation.
Topics: Acetamides; Aged; Ascites; Breath Tests; End Stage Liver Disease; Female; Humans; Liver Cirrhosis; L | 2015 |